Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS)
- Resource Type
- Article
- Source
- In
European Journal of Cancer June 2024 204 - Subject
DD - Language
- ISSN
- 0959-8049